이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

WuXi Biologics (Cayman) 미래 성장

Future 기준 확인 2/6

WuXi Biologics (Cayman) (는) 각각 연간 13.9% 및 12.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 13.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 10.2% 로 예상됩니다.

주요 정보

13.7%

수익 성장률

13.1%

EPS 성장률

Life Sciences 수익 성장	22.0%
매출 성장률	10.4%
향후 자기자본 수익률	10.2%
애널리스트 커버리지	Good
마지막 업데이트	26 Jun 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

DB:1FW1 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	23,738	5,463	2,546	7,092	23
12/31/2025	20,988	4,608	2,393	6,453	28
12/31/2024	18,120	3,846	399	5,858	26
12/31/2023	17,034	3,400	612	4,668	N/A
9/30/2023	16,794	3,776	N/A	N/A	N/A
6/30/2023	16,554	4,152	N/A	N/A	N/A
3/31/2023	15,911	4,286	N/A	N/A	N/A
12/31/2022	15,269	4,420	-327	5,542	N/A
9/30/2022	14,179	4,251	N/A	N/A	N/A
6/30/2022	13,090	4,081	-1,028	4,091	N/A
3/31/2022	11,690	3,735	-2,052	3,761	N/A
12/31/2021	10,290	3,388	-3,077	3,431	N/A
9/30/2021	9,183	3,092	-4,006	2,840	N/A
6/30/2021	8,075	2,795	-4,936	2,249	N/A
3/31/2021	6,844	2,242	-4,540	2,065	N/A
12/31/2020	5,612	1,689	-4,144	1,881	N/A
9/30/2020	4,967	1,494	-4,049	1,649	N/A
6/30/2020	4,321	1,300	-3,954	1,417	N/A
3/31/2020	4,152	1,157	-2,979	1,312	N/A
12/31/2019	3,984	1,014	-2,004	1,208	N/A
9/30/2019	3,535	922	-1,356	1,035	N/A
6/30/2019	3,087	831	-708	861	N/A
3/31/2019	2,811	731	-810	811	N/A
12/31/2018	2,534	631	-912	762	N/A
9/30/2018	2,277	520	-1,004	508	N/A
6/30/2018	2,019	410	-1,096	255	N/A
3/31/2018	1,819	331	-712	308	N/A
12/31/2017	1,619	253	-327	360	N/A
9/30/2017	1,429	177	N/A	320	N/A
6/30/2017	1,233	149	N/A	369	N/A
3/31/2017	1,111	145	N/A	226	N/A
12/31/2016	989	141	N/A	82	N/A
9/30/2016	889	171	N/A	162	N/A
12/31/2015	557	45	N/A	107	N/A
12/31/2014	332	42	N/A	22	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 1FW1 의 연간 예상 수익 증가율( 13.9% )이 saving rate( 0.7% 보다 높습니다. ).

수익 vs 시장: 1FW1 의 연간 수익( 13.9% ) German 시장( 18.5% 보다 느리게 성장할 것으로 예상됩니다. 18.5% 연간).

고성장 수익: 1FW1 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 1FW1 의 수익(연간 12.8% ) German 시장( 5.1% 보다 빠르게 성장할 것으로 예상됩니다. 5.1% 연간).

고성장 수익: 1FW1 의 수익(연간 12.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 1FW1 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 10.2 %).

WuXi Biologics (Cayman) 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Recent updates

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5

WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견